CCN2 and Hepatic fibrosis: In the hepatic fibrosis rat model, administered CLSN-CTGF-siRNA demonstrated high liver biodistribution after a single intravenous injection and showed significant improvement in liver function, manifesting in the decrease of circulating liver enzymes alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBIL), and total albumin (ALB).